Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Malin Corp PLC - investor in life sciences companies - Estimated intrinsic equity value per share at December 31 rises 7.4% to €9.34, from €8.70 a year earlier. Posts 2022 pretax profit of €12.3 million, swinging from loss of €3.8 million. ‘We have made significant progress in supporting our assets towards key milestones and value inflection points, which have catalysed value realisation opportunities,’ Chief Executive Darragh Lyons says. ‘As we look to the year ahead, we are confident that our investee companies can continue to progress their innovative technologies and clinical programmes with the aim of advancing important therapies for patients and creating significant value for their stakeholders.’ In addition, plans to return €140 million to shareholders at €9.30 per share by way of a tender offer.
‘We are delighted to continue to deliver on our long-standing commitment to return the excess capital of the business to our shareholders with this proposed return of up to €140 million by way of a tender offer,’ says Chair Liam Daniel.
Current stock price: €7.76
12-month change: up 6.9%
Copyright 2023 Alliance News Ltd. All Rights Reserved.